Ontology highlight
ABSTRACT:
SUBMITTER: Villanueva J
PROVIDER: S-EPMC3956616 | biostudies-literature | 2013 Sep
REPOSITORIES: biostudies-literature
Villanueva Jessie J Infante Jeffrey R JR Krepler Clemens C Reyes-Uribe Patricia P Samanta Minu M Chen Hsin-Yi HY Li Bin B Swoboda Rolf K RK Wilson Melissa M Vultur Adina A Fukunaba-Kalabis Mizuho M Wubbenhorst Bradley B Chen Thomas Y TY Liu Qin Q Sproesser Katrin K DeMarini Douglas J DJ Gilmer Tona M TM Martin Anne-Marie AM Marmorstein Ronen R Schultz David C DC Speicher David W DW Karakousis Giorgos C GC Xu Wei W Amaravadi Ravi K RK Xu Xiaowei X Schuchter Lynn M LM Herlyn Meenhard M Nathanson Katherine L KL
Cell reports 20130919 6
Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not respond to the BRAF inhibitor dabrafenib. We also identified the same MEK2-Q60P mutation along with BRAF amplification in a xenograft tumor derived from a second melanoma patient resistant to the combination of dabrafenib and trametinib. Melanoma ce ...[more]